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EDIToRIAL
Radical extrapleural pneumonectomy (EPP), and pleurectomy and decortication (P/D) have emerged as the two main surgical treatments of malignant pleural mesothelioma 
(MPM). Until recently, EPP has been considered the gold standard operation with P/D 
being performed if the patient’s physical status or preference dictated it. The operative 
mortality of EPP is reported to be as high as 18% in some series that has generated interest 
in studying the P/D procedure more intensively because of lesser complications and pos-
sibly better survival rates reported. Flores et al.1 reported on a series of 663 patients who 
underwent either EPP or P/D as part of their treatment for MPM . This is the largest series 
to date examining the outcomes of P/D as a modality of treatment for MPM. Their results 
demonstrate that there may be circumstances, such as in stage-I disease where an R0 resec-
tion is attained, in which P/D is a superior, less-morbid therapy. Likewise there may be a 
benefit to EPP in patients who have more extensive disease (stage II). This data suggests 
that the main therapeutic utility of any surgical therapy for MPM is in the possibility of 
attaining a complete macroscopic resection.1,2
The Mesothelioma and Radical Surgery (MARS) trial recently published the results 
of a trial randomizing 50 patients to the best therapy possible with or without EPP.3 The 
findings concluded by the authors suggest that because of the high morbidity of EPP it 
should be abandoned in the setting of trimodal therapy. The study was met with criticism 
on several grounds, namely the excessively high surgical mortality rate and the small sam-
ple size prohibiting significant power analysis.4,5 Given these recently published studies it is 
no wonder that there is currently a significant amount of controversy surrounding treatment 
recommendations for MPM.
The current study by Lang-Lazdunski et al.6 analyzes their significant experience in 
using both EPP and P/D to treat MPM. The study has the advantage of a single surgeon at a 
single institution performing all of the procedures as well as a large number of procedures 
over a relatively short (7-year) period. The reported surgical mortality is excellent at 4.5% 
for EPP and nil for the P/D group. The authors wisely point out that the technique of P/D 
is not standard everywhere. Two aspects of the P/D arm are unusual in the present study 
compared with those in studies at other centers, namely the hyperthermic providone/iodine 
lavage and the prophylactic low-dose radiation treatment postoperatively. The authors 
state that in all of the parameters evaluated patients undergoing P/D have a significantly 
improved survival rate. This includes stratification by preoperative stage and histology. The 
authors’ conclusion that further studies randomizing patients with MPM should use P/D as 
the standard surgical procedure aligns with the suggestion from the MARS trial that EPP 
be abandoned.
The study has several flaws that the authors recognized as well but the leap in transi-
tion of treatment away from EPP or any surgical therapy in the treatment of MPM should 
be made more cautiously. Although the authors do list the global reasons stating why a 
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patient may be excluded from EPP they do not analyze further 
the real trends in the decision making regarding the decision 
to pursue EPP versus P/D. For example, it would be helpful 
to know if the main reasons were related to physical status or 
patient preference. In addition, even though the demographic 
features are consistent with the two groups there has to be a 
more common reason why patients are steered toward P/D. 
If it is because of performance status or lung function, illus-
trating this data would only strengthen the argument for P/D 
as these patients would have survived longer than their more 
healthy functional counterparts undergoing EPP. In addition, 
the conclusion that patients survive longer on a stage-for-stage 
basis is unfounded given the extremely small sample size once 
the study groups are broken down into stage designations. The 
results of these prior studies that suggest there is a stage dif-
ference in the outcome of treatment speaks to the biology of 
the disease. Flores et al.1 suggest that there may be a benefit to 
performing different procedures for different stages of the dis-
ease. This makes sense given that the progression of disease 
from a pleural disease with no lung invasion (T1) to a disease 
where the only physical way to remove all macroscopic tumor 
is to perform some kind of lung resection (T2 and T3) suggests 
that different methods of local control may play a role at each 
stage of the disease. Both this trial and the MARS trial suffer 
from the fact that this notion is not recognized. It is helpful 
to examine the results of both this trial and the MARS trial 
concurrently as they both illustrate the difficulty in studying 
and providing recommendations for relatively rare diseases. 
MPM is not a heterogeneous disease, and as in other cancers 
it may not be wise to apply blanket statements recommending 
the treatment of the disease in any particular manner.
In conclusion, the results of the current study by Lang-
Lazdunski et al. provide additional data that should lead us to 
consider P/D in all trials of treatment for MPM. It is too early 
based on this data to completely abandon EPP altogether as 
there may be patient subsets where the potential reward out-
weighs the risk of the procedure.
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